Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338828 · ClinicalTrials.gov registry record · Phase 2
Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04338828: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04338828 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04338828, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requiring ICU admission and ventilatory support. While COVID-19 patients have an increased need for supportive care, there is currently no specific treatment directed against 2019-nCoV. Nitric oxide inhalation has been used as a pulmonary vasodilator and has been found to have antiviral activity against other coronavirus strains. The primary aim of this study is to determine whether inhaled NO improves short term respiratory status, prevents future hospitalization, and improves the clinical course in patients diagnosed with COVID-19 specifically in the emergency department.
Interventions
- DRUG Nitric Oxide Gas
- OTHER Inhaled Supplemental Oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-04-18 |
| Est. Completion | 2021-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04338828
The ClinicalTrials.gov registry entry for NCT04338828 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nitric Oxide Gas is the first listed.
NCT04338828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04338828 about?
NCT04338828 is a clinical study titled "Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED". The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requiring ICU admission and ventilatory support. While COVID-19 patients have an increased need for suppo...
What is the current status of trial NCT04338828?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2020-04-18. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT04338828?
The interventions under investigation include: Nitric Oxide Gas (DRUG), Inhaled Supplemental Oxygen (OTHER).
Who is sponsoring clinical trial NCT04338828?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.